Cryptococcal meningitis resistant to Fluconazole treatment: a case report
DOI:
https://doi.org/10.34119/bjhrv8n2-224Keywords:
meningitis, Cryptococcus spp., Fluconazole, AIDS, case reportAbstract
Justification: Cryptococcal meningitis is the second most common opportunistic infection in AIDS patients and is associated with high mortality rates. The antifungal agents proven effective in treating cryptococcosis include amphotericin B, fluconazole, and flucytosine. The prevalence of Cryptococcus spp. resistance to fluconazole varies by region and population. Case Report: Here, we report a fatal case of fluconazole-resistant cryptococcal meningitis in an immunosuppressed adult with AIDS. Severe liver dysfunction hindered effective treatment, while fluconazole resistance further restricted therapeutic options. Conclusions: Cryptococcal meningitis remains a major cause of morbidity and mortality worldwide, especially among AIDS patients. Early and appropriate antifungal treatment is crucial for improving outcomes. The growing concern over Cryptococcus spp. resistance to fluconazole remains poorly understood, highlighting the need for further studies to optimize early treatment strategies.
References
BASSO, L.R. et al. Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans. J AntimicrobChemother. 2015;70(5):1396-407.
BONGOMIN, F. et al. A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species. Mycoses. 2018;61(5):290-297.
CHANG, C.C. et al. Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM. Lancet Infect Dis. 2024;24(8):e495-e512.
CHANG, M. et al. Roles of Three Cryptococcus neoformans and Cryptococcus gattii Efflux Pump-Coding Genes in Response to Drug Treatment. Antimicrob Agents Chemother. 2018;62(4):e01751-17.
FIRACATIVE, C. et al. Recent Advances in Cryptococcus and Cryptococcosis. Microorganisms. 2021;10(1):13.
KON, A.S. et al. Consenso em criptococose – 2008. Rev Soc Bras Med Trop, v. 41, n. 5, p. 524-544, set./out. 2008.
KWON-CHUNG, K.J. et al.Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring HarbPerspect Med. 2014; 4(7):a019760.
MELHEM, M.S. et al. Antifungal Resistance in Cryptococcal Infections. Pathogens. 2024;13(2):128.
RAJASINGHAN, R. et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873-881.
RODERO, L. et al. G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate. Antimicrob Agents Chemother. 2003;47(11):3653-6.
SIONOV, E. et al. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 2010;6(4):e1000848.
STOVER, K.R. et al. Antifungal resistance, combinations and pipeline: oh my! Drugs Context. 2023;12:2023-7-1.
